July 16, 2019
1 min read
Save

FDA rejects Eton’s allergic conjunctivitis drop

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has rejected Eton Pharmaceuticals’ EM-100 for the treatment of ocular itching associated with allergic conjunctivitis, according to a press release.

Eton’s partner, Bausch Health Companies, which acquired the U.S. rights to EM-100 in February, received a complete response letter from the FDA regarding the filing.

The letter did not raise concerns about the clinical data, leaving the company optimistic about EM-100’s future.

“We believe the issues cited in the CRL can be addressed in the coming months, and we remain confident that EM-100 will be available to patients as quickly as possible,” Eton’s CEO Sean Brynjelsen said in the release.